Form 8-K - Current report:
SEC Accession No. 0001213900-25-005521
Filing Date
2025-01-22
Accepted
2025-01-22 16:35:01
Documents
16
Period of Report
2025-01-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228132-8k_onconetix.htm   iXBRL 8-K 30394
2 SETTLEMENT AGREEMENT, DATED JANUARY 15, 2025 ea022813201ex99-1_onconetix.htm EX-99.1 32203
3 LINKEDIN POSTING, DATED JANUARY 22, 2025 ea022813201ex99-2_onconetix.htm EX-99.2 1131
7 GRAPHIC ex99-2.jpg GRAPHIC 568968
  Complete submission text file 0001213900-25-005521.txt   1033584

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20250115.xsd EX-101.SCH 3042
5 XBRL LABEL FILE onco-20250115_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE onco-20250115_pre.xml EX-101.PRE 22377
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0228132-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 25546360
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)